Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside
Cardiovascular Research · 02.05.2023 · 119 (3) · 631-646
DOI: 10.1093/cvr/cvac105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 05.07.2022. Verfasst von Johny Nicolas und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medic…. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Coronary Artery Disease. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
Coronary stents have revolutionized the treatment of coronary artery disease. Compared with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel closure but were limited by in-stent restenosis (ISR) due to smooth muscle cell proliferation and neointimal hyperplasia. The first-generation drug-eluting stent (DES), with its antiproliferative drug coating, offered substantial advantages over BMSs as it mitigated the risk of ISR. Nonetheless, they had several design limitations that increased the risk of late stent thrombosis. Significant advances in stent design, including thinner struts, enhanced polymers’ formulation, and more potent antiproliferative agents, have led to the introduction of new-generation DES with a superior safety profile. Cardiologists have over 20 different DES types to choose from, each with its unique features and characteristics. This review highlights the evolution of stent design and summarizes the clinical data on the different stent types. We conclude by discussing the clinical implications of stent design in high-risk subsets of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Zena and Michael A. Wiener Cardiovascular Institute, Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY…
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090 Pieve Emanuele MI, Italy.
- IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy.
- Cardiovascular Department, Humanitas Gavazzeni, Via Mauro Gavazzeni, 21, 24125 Bergamo BG, Italy.
ORCID-Profile: Johny Nicolas, Mauro Chiarito, Frans Beerkens
Zitieren
APA
Nicolas, J., Pivato, C. A., Chiarito, M., Beerkens, F., Cao, D., & Mehran, R. (2023). Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovascular Research, 119(3), 631-646. https://doi.org/10.1093/cvr/cvac105
Vancouver
Nicolas J, Pivato CA, Chiarito M, Beerkens F, Cao D, Mehran R. Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovascular Research. 2023;119(3):631-646. doi:10.1093/cvr/cvac105
BibTeX
@article{Nicolas2023,
author = {Nicolas, Johny and Pivato, Carlo Andrea and Chiarito, Mauro and Beerkens, Frans and Cao, Davide and Mehran, Roxana},
title = {Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {3},
pages = {631--646},
doi = {10.1093/cvr/cvac105}
}
EUVIMED